0800 Immune

0800 466 863


Pertussis and influenza immunisation coverage of pregnant women in New Zealand

Background: Immunisation is an important public health policy and measuring coverage is imperative to
identify gaps and monitor trends. New Zealand (NZ), like many countries, does not routinely publish coverage
of immunisations given during pregnancy. Therefore, this study examined pregnancy immunisation
coverage of all pregnant NZ women between 2013 and 2018, and what factors affected uptake.
Methods: A retrospective cohort study of pregnant women who delivered between 2013 and 2018 was

Age is not just a number - synopsis of the 5th New Zealand Influenza Symposium 2019


This paper is a summary of the 5th New Zealand Influenza Symposium run by the Immunisation Advisory Centre in collaboration with the Ministry of Health. National and international presenters discussed improving the uptake of the influenza vaccine in New Zealand, and the severity and consequences of influenza, particularly for the elderly and those with chronic health issues. Highlighted were the benefits of influenza vaccination and how it can reduce declines in cognitive and physical health that can lead to loss of independence for older people.

Review of evidence to inform the New Zealand National Immunisation Schedule, 2019: Pneumococcal

A primary aim of pneumococcal immunisation programmes is to prevent invasive pneumococcal disease (IPD), defined as infection of Streptococcus pneumoniae in the blood or other normally sterile sites, with associated hospitalisations and deaths. Pneumococci also cause respiratory tract infections without bacteraemia; the most severe of which is pneumococcal pneumonia, but also include middle-ear infection (acute otitis media) and sinusitis.

A Retrospective Cohort Study of Safety Outcomes in New Zealand Infants Exposed to Tdap Vaccine in Utero

We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age.

Influences and policies that affect immunisation coverage - a review of literature

To provide adequate direct and indirect protection against vaccine-preventable diseases (VPD), a high proportion of the population needs to be immune. Specific immunity against certain diseases can be achieved through immunisation with vaccines or exposure to the pathogen itself. The aim of immunisation programmes is to generate immunity in individuals and within the community to prevent the spread of disease and to reduce the impact of such diseases.

Vaccine-Preventable Disease-Associated Hospitalisations Among Migrant and Non-migrant Children in New Zealand

Migrants may experience a higher burden of vaccine-preventable disease (VPD)-associated hospitalisations compared to the host population. A retrospective cohort study from 2006 to 2015 was conducted that linked de-identified data from government sources using Statistic NZ’s Integrated Data Infrastructure. VPD-related hospitalisations were compared between three cohorts of children from birth to 5 years old: foreign-born children who migrated to NZ, children born in NZ of recent migrant mothers, and a comparator group of children born in NZ without a recent migration background.

Review of evidence to inform the New Zealand National Immunisation Schedule, 2018: Pertussis

Even with immunisation programmes, pertussis remains a significant cause of morbidity and mortality worldwide. Infants are especially vulnerable to this highly contagious bacterial infection due to the immaturity of their immune and respiratory systems.